Calidi Biotherapeutics (CLDI) Share-based Compensation (2022 - 2025)
Calidi Biotherapeutics' quarterly Share-based Compensation came in at $450000.0 in Q4 2025, down 28.12% year-on-year from $626000.0 in Q4 2024, and down 14.93% quarter-over-quarter from $529000.0 in Q3 2025.
Calidi Biotherapeutics has reported Share-based Compensation for 4 years, with the latest figure at $450000.0 in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 28.12% year-over-year to $450000.0; the trailing twelve-month figure through Dec 2025 stood at $2.1 million (down 28.69% YoY), and the FY2025 full-year result was $2.1 million, down 28.71% from the prior year.
- Share-based Compensation for Q4 2025 stood at $450000.0, down from $529000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.4 million in Q1 2023, with the low at $450000.0 in Q4 2025.
- Average Share-based Compensation over 4 years is $856642.9, with a median of $819500.0 recorded in 2024.
- Year-over-year, Share-based Compensation increased 12.1% in 2023 and sank 47.22% in 2024.
- Tracing CLDI's Share-based Compensation over 4 years: stood at $1.1 million in 2022, then increased by 12.1% to $1.2 million in 2023, then tumbled by 47.22% to $626000.0 in 2024, then slipped by 28.12% to $450000.0 in 2025.
- The last three Share-based Compensation figures came in at $450000.0 (Q4 2025), $529000.0 (Q3 2025), and $522000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | 450,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 450,000.00 |
| Dec 31, 2025 | 450,000.00 |
| Sep 30, 2025 | 529,000.00 |
| Sep 30, 2025 | 529,000.00 |
| Jun 30, 2025 | 522,000.00 |
| Jun 30, 2025 | 522,000.00 |
| Mar 31, 2025 | 607,000.00 |
| Mar 31, 2025 | 607,000.00 |
| Dec 31, 2024 | 626,000.00 |
| Dec 31, 2024 | 626,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 751,000.00 |
| Jun 30, 2024 | 751,000.00 |
| Mar 31, 2024 | 888,000.00 |
| Mar 31, 2024 | 888,000.00 |
| Dec 31, 2023 | 1.19 Mn |
| Dec 31, 2023 | 1.19 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.08 Mn |
| Mar 31, 2023 | 1.43 Mn |
| Mar 31, 2023 | 1.43 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 1.06 Mn |
| Sep 30, 2022 | 1.06 Mn |